These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The clinical characteristics of Takayasu's arteritis with glomerulonephropathy].
    Author: Chen Z, Yang YJ, Li J, Tian XP.
    Journal: Zhonghua Nei Ke Za Zhi; 2018 Feb 01; 57(2):129-133. PubMed ID: 29397599.
    Abstract:
    Objective: To investigate the clinical features of Takayasu's arteritis (TAK) with glomerulonephropathy and to improve physicians' understanding of this complication in patients with TAK. Methods: Clinical data were retrospectively collected including manifestations, laboratory tests, image findings and treatment of 8 patients diagnosed as Takayasu's arteritis with glomerulonephropathy from January 2002 to January 2017 in Peking Union Medical College Hospital. Results: Glomerulonephropathy was confirmed based on percutaneous renal biopsy. There were 6 women and 2 men. The median onset age and median disease duration were 24 (18-37) years and 42 (3-360) months, respectively. Five patients had hypertension. The 24 hour urinary protein was 0.18-14.91 g. Red blood cells and casts in urine were tested among 4 and 2 patients, respectively. Three patients had renal artery stenosis. Three patients demonstrated mesangial proliferative glomerulonephritis, two with IgA nephropathy, two with minimal change disease and one with membranoproliferative glomerulonephritis. Seven patients received glucocorticoid combined with cyclophosphamide therapy (glucocorticoid 40-60 mg/d, prednisone or equivalent; cyclophosphamide 0.4 g/week iv. or cyclophosphamide 0.1 g/d po.). Uninary blood cells removed and 24 hour urinary protein decreased from 1.65 g to 0.90 g after treatment for 12 months in one patient. The other 7 patients were missing. Conclusion: Glomerulonephropathy is occasionally observed among TAK patients. Mesangial proliferative glomerulonephritis is the most common pathological subtype. Glucocorticoid combined with cyclophosphamide therapy could be an optional therapy for Takayasu's arteritis with glomerulonephropathy. 目的：通过分析总结多发性大动脉炎（TAK）合并肾小球疾病患者的临床资料，提高临床医生对其的认识水平。 方法：回顾性分析2002年1月至2017年1月北京协和医院住院诊治的8例经肾穿刺活检病理证实的TAK合并肾小球疾病患者的临床资料，包括临床表现、实验室及影像学检查及治疗方案。 结果： 8例TAK合并肾小球疾病患者男性2例，女性6例，中位起病年龄24（18~37）岁，中位病程42（3~360）个月。5例患者患有高血压。24 h尿蛋白定量0.18~14.91 g，4例尿红细胞阳性，1例尿沉渣中有透明管型，1例尿沉渣中有颗粒管型。3例患者有肾动脉狭窄。3例患者肾组织活检病理结果为系膜增生性肾小球肾炎，2例为IgA肾病，2例为微小病变肾病，1例为膜增生性肾小球肾炎。7例患者接受糖皮质激素联合环磷酰胺治疗[糖皮质激素40~60 mg/d（以等效泼尼松剂量计算）；环磷酰胺为0.4 g/周、静脉注射或0.1 g/d、口服]。1例患者经治疗后尿红细胞消失，24 h尿蛋白定量由1.65 g降至0.9 g，随访12个月；7例患者均失访。 结论： TAK患者可合并肾小球疾病，系膜增生性肾小球肾炎是最常见的肾脏病理类型，糖皮质激素联合环磷酰胺可作为治疗的选择。.
    [Abstract] [Full Text] [Related] [New Search]